Carmelo Escudero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmelo Escudero has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Pablo Rodríguez del Río
Allergy Department Hospital Infantil Universitario Niño Jesús Madrid Spain
4 shared publications - Montserrat Fernández‐Rivas
Allergy Department Hospital Clinico San Carlos, IdISSC Madrid Spain
2 shared publications - Raphaëlle Bazire
Allergy Department Hospital Infantil Universitario Niño Jesús, Fundación Hospital Niño Jesús (HNJ), IIS‐Princesa Madrid Spain
2 shared publications - Alicia Alonso‐Gómez
Hospital Felipe II Recoletas Valladolid Spain
1 shared publication - Alvaro Moreno-Ancillo
Allergy Section Hospital General Universitario Nuestra Señora del Prado Talavera de la Reina Toledo Spain
1 shared publication - Anna Nowak-Wegrzyn
Department of Pediatrics, Hassenfeld Children's Hospital, NYU Grossman School of Medicine, New York, New York; Department of Pediatrics, Gastroenterology and Nutrition, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
1 shared publication
Latest Publications
- 19 November 2026
- Published by Wiley in Clinical & Experimental Allergy
NavigAIT.me, a Digital Intervention to Improve Long‐Term Adherence in Allergen Immunotherapy: Design of a Multicentre Randomised Trial
Summary: Evaluating the real‐life effectiveness of a new digital intervention to improve persistence in allergen immunotherapy (AIT). Assessing persistence, implementation, effectiveness and satisfaction with AIT in a randomised controlled prospective large‐scale trial.
- 19 November 2026
- Published by Wiley in Clinical & Experimental Allergy
NavigAIT.me, a Digital Intervention to Improve Long‐Term Adherence in Allergen Immunotherapy: Design of a Multicentre Randomised Trial
Summary: Evaluating the real‐life effectiveness of a new digital intervention to improve persistence in allergen immunotherapy (AIT). Assessing persistence, implementation, effectiveness and satisfaction with AIT in a randomised controlled prospective large‐scale trial.
- 31 May 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70364
Two cases of severe apple‐induced reactions and sensitization to gibberellin‐regulated proteins: A diagnostic challenge
- 31 May 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70364
Two cases of severe apple‐induced reactions and sensitization to gibberellin‐regulated proteins: A diagnostic challenge
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta‐analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO‐FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient‐reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.
Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
Food allergy is a global public health problem that until recent years lacked any aetiological treatment supported by academy, industry and regulators. Food immunotherapy (AIT) is an evolving treatment option, supported by clinical practice and industry trial data. Recent AIT meta‐analyses have highlighted the difficulty in pooling safety and efficacy data from AIT trials, due to secondary heterogeneity in the study. An EAACI task force (CO‐FAITH) initiated by the Paediatric Section was created to focus on AIT efficacy outcomes for milk, egg and peanut allergy rather than in trial results. A systematic search and a narrative review of AIT controlled clinical trials and large case series was conducted. A total of 63 manuscripts met inclusion criteria, corresponding to 23, 21 and 22 studies of milk, egg and peanut AIT, respectively. The most common AIT efficacy outcome was desensitization, mostly defined as tolerating a maintenance phase dose, or reaching a particular dose upon successful exit oral food challenge (OFC). However, a large degree of heterogeneity was identified regarding the dose quantity defining this outcome. Sustained unresponsiveness and patient‐reported outcomes (e.g. quality of life) were explored less frequently, and to date have been most rigorously described for peanut AIT versus other allergens. Change in allergen threshold assessed by OFC remains the most common efficacy measure, but OFC methods suffer from heterogeneity and methodological disparity. This review has identified multiple heterogeneous outcomes related to measuring the efficacy of AIT. Efforts to better standardize and harmonize which outcomes, and how to measure them must be carried out to help in the clinical development of safe and efficacious food allergy treatments.
- 25 June 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (3) , 250-272
Adverse Reactions to Anti-Infective Vaccines: an Emerging Problem in the COVID-19 Era
Purpose of review Vaccines are an essential tool for preventing infectious diseases and reducing associated morbidity and mortality. Vaccination has a significant impact at both individual and community levels, and COVID‐19 vaccination programs are a new example of the great value of this public health strategy. However, adverse reactions, especially severe reactions such as anaphylaxis, prevent these programs from progressing properly, thus limiting vaccination uptake in the population. Recent findings The frequency of reactions and types of vaccine components, with special attention to COVID-19 vaccines studies, provides information on the magnitude and causes of adverse events. The understanding of mechanisms involved has made it possible to adequately guide diagnosis, especially to COVID-19 vaccine components, such as polyethylene glycol, trometamol, and polysorbate-80. Summary This review focuses on adverse reactions to vaccines, with emphasis on allergic reactions. A diagnostic pathway is suggested that, on the one hand, enables to take the necessary precautions in persons with a history of allergy to vaccine components or allergic reactions to vaccines and, on the other, supports administration of subsequent doses. The overall objective is to ensure that people with allergy can be vaccinated in the same way as the rest of the population, and that they are offered alternatives where necessary.
- 25 June 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (3) , 250-272
Adverse Reactions to Anti-Infective Vaccines: an Emerging Problem in the COVID-19 Era
Purpose of review Vaccines are an essential tool for preventing infectious diseases and reducing associated morbidity and mortality. Vaccination has a significant impact at both individual and community levels, and COVID‐19 vaccination programs are a new example of the great value of this public health strategy. However, adverse reactions, especially severe reactions such as anaphylaxis, prevent these programs from progressing properly, thus limiting vaccination uptake in the population. Recent findings The frequency of reactions and types of vaccine components, with special attention to COVID-19 vaccines studies, provides information on the magnitude and causes of adverse events. The understanding of mechanisms involved has made it possible to adequately guide diagnosis, especially to COVID-19 vaccine components, such as polyethylene glycol, trometamol, and polysorbate-80. Summary This review focuses on adverse reactions to vaccines, with emphasis on allergic reactions. A diagnostic pathway is suggested that, on the one hand, enables to take the necessary precautions in persons with a history of allergy to vaccine components or allergic reactions to vaccines and, on the other, supports administration of subsequent doses. The overall objective is to ensure that people with allergy can be vaccinated in the same way as the rest of the population, and that they are offered alternatives where necessary.
- 3 March 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (3) , e13757
COVID‐19 and childhood asthma: Analysis of a pediatric referral hospital
- 3 March 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (3) , e13757
COVID‐19 and childhood asthma: Analysis of a pediatric referral hospital
- Open Access
- 1 January 2014
- Published by Elsevier in World Allergy Organization Journal
- Vol. 7 (1) , 1-11
Immunological cross-reactivity between olive and grass pollen: implication of major and minor allergens
- 1 January 2014
- Published by Elsevier in World Allergy Organization Journal
- Vol. 7 (1) , 1-11
Open AccessImmunological cross-reactivity between olive and grass pollen: implication of major and minor allergens